Enlivex Therapeutics reports 2025 AGM results with all items passed

Rhea-AI Filing Summary

Enlivex Therapeutics Ltd. (ENLV) reported that it held its 2025 Annual General Meeting of Shareholders on November 17, 2025. Shareholders voted on proposals described in the earlier notice and proxy statement, and each proposal was approved by the required majority. The company also stated that this report is incorporated by reference into its existing registration statements on Forms S-8 and F-3, which helps keep those filings updated with its latest corporate actions.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of: November 2025

Commission file number: 001-36578

ENLIVEX THERAPEUTICS LTD.

(Translation of registrant’s name into English)

14 Einstein Street, Nes Ziona, Israel 7403618

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Annual General Meeting of Shareholders

On November 17, 2025, Enlivex Therapeutics Ltd., a company organized under the laws of the State of Israel (the “Company”), held its 2025 Annual General Meeting of Shareholders of the Company (the “Meeting”). At the Meeting, the shareholders voted on and approved, by the applicable required majority, each of the proposals that were described in the Company’s Notice and Proxy Statement for the Meeting that was attached as Exhibit 99.1 to a Report of Foreign Private Issuer on Form 6-K furnished by the Company to the U.S. Securities and Exchange Commission on September 25, 2025. The information contained in this Report on Form 6-K is hereby incorporated by reference into the Company’s registration statements on Forms S-8, F-3 and F-3MEF (File No. 333-256799, File No. 333-232413, File No. 333-232009, File No. 333-252926 and File No. 333-264561), filed with the Securities and Exchange Commission.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Enlivex Therapeutics Ltd.
	(Registrant)
	By:	/s/ Oren Hershkovitz
	Name: Title:	Oren Hershkovitz Chief Executive Officer

Date: November 18, 2025

2

FAQ

What did Enlivex Therapeutics Ltd. (ENLV) announce in this Form 6-K?

Enlivex Therapeutics Ltd. reported that it held its 2025 Annual General Meeting of Shareholders on November 17, 2025, and that all proposals presented at the meeting were approved by the required shareholder majority.

Were Enlivex (ENLV) shareholders’ proposals approved at the 2025 Annual General Meeting?

Yes. The company stated that shareholders voted on each of the proposals described in the notice and proxy statement for the meeting and approved all of them by the applicable required majority.

When did Enlivex Therapeutics (ENLV) hold its 2025 Annual General Meeting of Shareholders?

Enlivex Therapeutics held its 2025 Annual General Meeting of Shareholders on November 17, 2025.

Where can investors find the details of the proposals approved at Enlivex’s 2025 AGM?

The specific proposals are described in Enlivex’s Notice and Proxy Statement for the 2025 Annual General Meeting, which was attached as Exhibit 99.1 to a Form 6-K furnished to the U.S. Securities and Exchange Commission on September 25, 2025.

How does this Enlivex (ENLV) Form 6-K relate to the company’s registration statements?

The company stated that the information in this Form 6-K is incorporated by reference into its registration statements on Forms S-8, F-3 and F-3MEF, including several specified file numbers, helping keep those registration statements current.

Who signed the Enlivex Therapeutics (ENLV) Form 6-K related to the 2025 AGM?

The report was signed on behalf of Enlivex Therapeutics Ltd. by Oren Hershkovitz, who is identified as the company’s Chief Executive Officer.